target directory

flt3 mutations in acute myeloid leukemia aml clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT06696183

Source recordAI-normalized

Sequential Gilteritinib in Combination With Venetoclax and Azacitidine for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and FLT3 Mutations Ineligible for Intensive Treatment

The clinical trial, sponsored by Technische Universität Dresden, investigates the combination of Gilteritinib, Venetoclax, and Azacitidine in patients with newly diagnosed AML harboring FLT3 mutations who are ineligible for intensive chemotherapy. This patient population represents a significant unmet medical need, as current treatment options are limited for those unable to tolerate standard induction chemotherapy. The trial's focus on optimizing dosing regimens may enhance therapeutic outcomes and improve market positioning for Gilteritinib in the competitive landscape of AML therapies. Given the increasing prevalence of AML and the growing market for targeted therapies, successful trial outcomes could lead to expanded indications and increased market share for the involved compounds.

AI analysis

Indication: AML - Acute Myeloid Leukemia

Modality: small molecule

Target: FLT3 mutations in Acute Myeloid Leukemia (AML)

Sponsor: Technische Universität Dresden

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 14, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: FLT3 mutations in Acute Myeloid Leukemia (AML)

View original source fields

Condition raw: AML - Acute Myeloid Leukemia

Condition normalized: AML - Acute Myeloid Leukemia

Modality raw: small molecule

Modality normalized: small molecule

Target raw: FLT3 mutations in Acute Myeloid Leukemia (AML)

Target normalized: FLT3 mutations in Acute Myeloid Leukemia (AML)

Open report

NCT05445154

Source recordAI-normalized

A Single-Arm, Multicenter, Open-Label, Dose- Escalating and Expanding,Phase I/II Study of SKLB1028 Combined With "7+3" Standard Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

SKLB1028, developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., is currently undergoing a Phase I/II clinical trial to evaluate its safety, tolerability, and pharmacokinetics when combined with the standard '7+3' chemotherapy regimen in patients with newly diagnosed AML. The trial is particularly focused on patients with FLT3 mutations, a significant subset of AML that represents a substantial market opportunity due to the high unmet need for effective therapies. The competitive landscape includes other FLT3 inhibitors such as midostaurin and gilteritinib, which have established their efficacy in this patient population. Successful outcomes from this trial could position SKLB1028 as a viable treatment option, potentially enhancing CSPC's portfolio in the oncology space and providing a strategic advantage in the growing AML market.

AI analysis

Indication: Newly Diagnosed Acute Myeloid Leukemia (AML)

Modality: small molecule

Target: FLT3 mutations in acute myeloid leukemia (AML)

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 10, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: FLT3 mutations in acute myeloid leukemia (AML)